Halaven

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
02420102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
AIM To identify conditions that induce an increase in the sensitivity of highly Halaven (HAL)-resistant cancer cells compared to… (More)
Is this relevant?
2015
2015
Eribulin mesylate (Halaven) is a microtubule-targeted anticancer drug used to treat patients with metastatic breast cancer who… (More)
Is this relevant?
2015
2015
Background: Trial data often does not cover a sufficiently long period of time to truly capture time-toevent endpoints, however… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Review
2013
Review
2013
OBJECTIVES Cancer affects the health of many people globally. The most common treatment that is used for cancer is chemotherapy… (More)
Is this relevant?
Review
2012
Review
2012
OBJECTIVE To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of eribulin (Halaven). DATA SOURCES A… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2011
Review
2011
Although metastatic breast cancer remains essentially incurable, many patients previously treated with an anthracycline, taxane… (More)
Is this relevant?
2011
2011
  • The Medical letter on drugs and therapeutics
  • 2011
Eribulin mesylate (Halaven-Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have… (More)
Is this relevant?
2011
2011
Eribulin mesylate (Halaven; Eisai) — a synthetic analogue of the marine natural product halichondrin B that interferes with… (More)
  • figure 1
Is this relevant?
2011
2011
Marine macrolides that selectively disrupt cell cycle events continue to occupy a central position as lead compounds in the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?